Clinical Trial for patients with acute/sub-acute spinal cord injury!
Phase II European Clinical Trial on Regenerative Cell Therapy for acute and sub-acute spinal cord injuries.
Randomised and placebo-controlled trial with an early and late intervention crossover design.
Conducted under official approval from the Spanish and Danish medical ethical committees Comité de Ética de la Investigación con medicamentos (CEIm) and National Videnskabsetisk Komité (NVK) and the competent authorities Agencia Espańola de Medicamentos y Productos Sanitarios (AEMPS) and the Danish Medicines Agency
Performed in Spain
INCLUSION CRITERIA / INDICATION:
Disease: acute trauma to the spinal cord: A, B or C lesion - between C4 and T12 while self-breathing ability should be present!
Timeline: 6 to 10 weeks after sustaining the trauma
Gender: Male and female patients
Age: adults - 18 years to 65 years
Registration: after case assessment / before August 2022
Patients meeting inclusion criteria may contact us for further evaluation and details.